Monoclonal Antibodies

• Autores: Larisa J. Geskin
• Localización: Dermatologic clinics, ISSN 0733-8635, Vol. 33, Nº. 4, 2015 (Ejemplar dedicado a: Cutaneous Lymphoma), págs. 777-786
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Use of monoclonal antibodies (mAbs) has revolutionized cancer therapy. Approaches targeting specific cellular targets on the malignant cells and in tumor microenvironment have been proved to be successful in hematologic malignancies, including cutaneous lymphomas. mAb-based therapy for cutaneous T-cell lymphoma has demonstrated high response rates and a favorable toxicity profile in clinical trials. Several antibodies and antibody-based conjugates are approved for use in clinical practice, and many more are in ongoing and planned clinical trials. In addition, these safe and effective drugs can be used as pillars for sequential therapies in a rational stepwise manner.